Details for New Drug Application (NDA): 020723
✉ Email this page to a colleague
The generic ingredient in ALDARA is imiquimod. There are fourteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the imiquimod profile page.
Pharmacology for NDA: 020723
Mechanism of Action | Interferon Inducers |
Physiological Effect | Increased Cytokine Activity Increased Cytokine Production |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | CREAM;TOPICAL | Strength | 5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Feb 27, 1997 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Oct 1, 2024 | Product Flag? | Substance Flag? | Delist Request? | Y |
Expired US Patents for NDA 020723
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bausch | ALDARA | imiquimod | CREAM;TOPICAL | 020723-001 | Feb 27, 1997 | ⤷ Sign Up | ⤷ Sign Up |
Bausch | ALDARA | imiquimod | CREAM;TOPICAL | 020723-001 | Feb 27, 1997 | ⤷ Sign Up | ⤷ Sign Up |
Bausch | ALDARA | imiquimod | CREAM;TOPICAL | 020723-001 | Feb 27, 1997 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription